Gritstone bio (NASDAQ:GRTS) Rating Reiterated by HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Gritstone bio (NASDAQ:GRTS) in a research report report published on Thursday, Benzinga reports. They currently have a $4.00 price objective on the stock.

Other equities research analysts also recently issued research reports about the stock. JMP Securities reaffirmed a market outperform rating and issued a $5.00 target price on shares of Gritstone bio in a research report on Monday, August 5th. B. Riley reissued a buy rating and set a $3.00 price objective (down previously from $6.00) on shares of Gritstone bio in a research report on Friday, May 24th.

Gritstone bio Trading Down 5.7 %

NASDAQ:GRTS opened at $0.50 on Thursday. The company has a current ratio of 2.00, a quick ratio of 2.00 and a debt-to-equity ratio of 2.89. Gritstone bio has a 12 month low of $0.45 and a 12 month high of $3.33. The company has a market cap of $54.30 million, a PE ratio of -0.40 and a beta of 0.50. The company has a 50 day simple moving average of $0.64 and a two-hundred day simple moving average of $1.24.

Gritstone bio (NASDAQ:GRTS) last posted its earnings results on Tuesday, August 13th. The company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.12. Gritstone bio had a negative net margin of 926.13% and a negative return on equity of 232.42%. The business had revenue of $0.92 million during the quarter, compared to the consensus estimate of $2.77 million. Research analysts forecast that Gritstone bio will post -0.99 earnings per share for the current year.

Institutional Investors Weigh In On Gritstone bio

Hedge funds have recently modified their holdings of the business. Tidal Investments LLC purchased a new position in shares of Gritstone bio during the 1st quarter valued at $63,000. Lazard Asset Management LLC purchased a new position in shares of Gritstone bio during the 1st quarter valued at $70,000. Klingman & Associates LLC purchased a new position in shares of Gritstone bio during the 1st quarter valued at $89,000. BNP Paribas Financial Markets lifted its stake in shares of Gritstone bio by 85.2% during the 1st quarter. BNP Paribas Financial Markets now owns 46,237 shares of the company’s stock valued at $119,000 after buying an additional 21,271 shares in the last quarter. Finally, Point72 DIFC Ltd purchased a new position in shares of Gritstone bio during the 2nd quarter valued at $29,000. Institutional investors own 48.46% of the company’s stock.

About Gritstone bio

Gritstone bio, Inc, a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, an individualized immunotherapy candidate, which is in Phase 2/3 clinical trials for the treatment of microsatellite stable colorectal cancers; and has completed Phase 1/2 clinical trials for treating solid tumors.